Credit Ratings
-
S&P Raises Teva to ‘BB+’ on Growth Strategy Success, Moody’s Eyes Positive Outlook
Teva Pharmaceutical Industries has received upgraded credit ratings and a positive outlook from S&P and Moody’s. These actions reflect the company’s successful “Pivot to Growth” strategy, evidenced by consistent deleveraging and a return to revenue growth. Strong performance in branded medicines and upcoming biosimilar launches are key drivers, offsetting generics headwinds. This signifies Teva’s progress toward financial health and potentially investment-grade status.
